^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iberdomide (CC-220)

    i
    Other names: CC-220, CC 220, CC220
    Company:
    BMS
    Drug class:
    CRL4-CRBN E3 ubiquitin ligase modulator
    Related drugs:
    7d
    Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=720, Not yet recruiting, Dana-Farber Cancer Institute
    New P3 trial
    |
    TP53 (Tumor protein P53)
    |
    clonoSEQ®
    |
    bortezomib • dexamethasone • iberdomide (CC-220) • Lynozyfic (linvoseltamab-gcpt) • Sarclisa subcutaneous (isatuximab subcutaneous) • captisol-enabled melphalan
    10d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Oct 2026 --> Aug 2028 | Trial primary completion date: Apr 2026 --> Aug 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ®
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    19d
    Isa Iber VD: A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant (clinicaltrials.gov)
    P1/2, N=88, Not yet recruiting, Dana-Farber Cancer Institute
    New P1/2 trial
    |
    bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • iberdomide (CC-220)
    24d
    Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    iberdomide (CC-220)
    29d
    Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=26, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecvayli (teclistamab-cqyv) • iberdomide (CC-220)
    1m
    GEM-IBERDARAX: Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. (clinicaltrials.gov)
    P2, N=140, Active, not recruiting, PETHEMA Foundation | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Darzalex (daratumumab) • dexamethasone • iberdomide (CC-220)
    1m
    Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer. (PubMed, J Proteome Res)
    Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.
    Journal
    |
    IKZF2 (IKAROS family zinc finger 2)
    |
    pomalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    2ms
    Advances in multiple myeloma: key updates from the ASH 2025 meeting. (PubMed, J Hematol Oncol)
    In newly diagnosed MM (NDMM), minimal residual disease (MRD)-adaptive consolidation with linvoseltamab in IMMUNOPLANT converted persistent MRD positivity to MRD negativity in all evaluable patients, supporting biologically guided treatment intensification...In early relapsed/refractory MM (RRMM), the pioneering phase III MajesTEC-3 trial demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits with BsAb teclistamab plus daratumumab compared to other standard triplets, with response rates approaching those historically observed with chimeric antigen receptor (CAR) T cell therapy. A novel rational BsAb combination of BsAb elranatamab anda cereblon E3 ligase modulatory drug (CELMoD) iberdomide in MagnetisMM-30 showed promising synergy despite cytopenias and updates to combination BsAb targeting in RedirecTT-1 demonstrated major activity in difficult to treat extramedullary myeloma (EMM). First-in-human inMMyCAR data showcased the forefront of engineered immune strategies, by introducing an in vivo CAR-T product as a proof-of-concept platform, with tremendous potential to streamline the access to therapy. Collectively, these studies signal a shift toward earlier and adaptive immunotherapy in all phases of MM disease, while underscoring the importance of infection mitigation and long-term safety evaluation.
    Journal • First-in-human
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • Elrexfio (elranatamab-bcmm) • Tecvayli (teclistamab-cqyv) • iberdomide (CC-220) • Lynozyfic (linvoseltamab-gcpt)
    2ms
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    2ms
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: May 2026 --> Jul 2026
    Trial initiation date
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)
    2ms
    EXCALIBER: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=939, Active, not recruiting, Celgene | Trial primary completion date: Mar 2026 --> Nov 2027
    Trial primary completion date
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    3ms
    Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=88, Recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Recruiting
    Enrollment open
    |
    dexamethasone • Blenrep (belantamab mafodotin-blmf) • iberdomide (CC-220)